IP Library › Granted Patent US 12,655,091
Granted Patent B2
US 12,655,091 · App. 18/267,330 · Granted Jun 16, 2026

N-benzyl-alpha-aminoamides as anaphase-promoting complex/cyclosome (APC/C) inhibitors

Inventors: Agatha Bastida Codina (Madrid, ES); Raúl Benito Arenas (Madrid, ES); Victor M. Bolanos-García (Oxford, GB); Natalie Laura Curtis (Oxford, GB)
Assignees: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC); OXFORD BROOKES UNIVERSITY
C07C237/20A61K31/165A61K31/27A61P35/00C07C237/06C07B2200/09
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,655,091
App. No.
18/267,330
Granted
Jun 16, 2026
Kind
B2
Abstract

The invention relates to a compound of formula I which are inhibitors of anaphase promoting complex/cyclosome (APC/C) function of formula I, wherein the meaning for R 1 and R 2 is as disclosed in the description. These compounds are useful in the treatment of cancer, particularly, in the treatment of breast cancer.

Claims (19)

1 . A compound of formula I:

or a pharmaceutical salt thereof, wherein:

R 1 represents —CF 3 ;

R 2 represents C 1 -C 6 alkyl substituted Cy 1 ;

Cy 1 represents a phenyl group (-Ph) substituted by —OH.

2 . The compound of formula I or a pharmaceutical salt thereof according to claim 1 , wherein Cy 1 represents a phenyl group (-Ph) substituted by —OH in para-position.

3 . The compound of formula I or a pharmaceutical salt thereof according claim 1 , wherein R 2 is a group of formula R 2 -a:

4 . The compound of formula I or a pharmaceutical salt thereof according to claim 1 , wherein the compound of formula I is selected from:

5 . The compound of formula I or a pharmaceutical salt thereof according to claim 4 , wherein the compound of formula I is:

6 . A pharmaceutical composition which comprises a compound of formula I according claim 1 or a pharmaceutically acceptable salt thereof andone or more pharmaceutically acceptable excipients.

7 . A pharmaceutical composition comprising a compound of formula I according to claim 1 , in combination with a further compound selected from pro-N-4-tosyl-L-arginine methyl ester (proTame).

8 . A method for the treatment of cancer comprising administering to a subject in need thereof an effective amount of a compound of formula I:

or a pharmaceutical salt thereof, wherein:

R 1 represents —CF 3 ;

R 2 represents C 1 -C 6 alkyl substituted Cy 1 ;

Cy 1 represents a phenyl group (-Ph) substituted by —OH,

and wherein the cancer is breast cancer.

9 . The method according to claim 8 , wherein the compound of formula I is selected from:

10 . The method according to claim 8 , wherein the compound of formula I is:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2023
From: BASTIDA CODINA, AGATHA; BENITO ARENAS, RAÚL; BOLANOS-GARCÍA, VICTOR M.; CURTIS, NATALIE LAURA
To: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC); OXFORD BROOKES UNIVERSITY
Reel/Frame 065921/0766 →
Priority Claims (1)
EP 20383100 · Dec 16, 2020 · regional
Continuity (1)
Related Publication 20240043374A1 · Feb 8, 2024
References Cited (17)
US 20040106794A1 · Taveras et al. · 2004 [cited by applicant]
US 20130230458A1 · King et al. · 2013 [cited by applicant]
WO WO2005082343A2 · 2005 [cited by examiner]
WO 2012031118A2 · 2012 [cited by applicant]
WO 2012149266A1 · 2012 [cited by applicant]
WO 2020210032A1 · 2020 [cited by applicant]
Amber M. King, “Primary Amino Acid Derivatives: Substitution of the 40-N0-Benzylamide Site in (R)-N0-Benzyl 2-Amino-3-methylbutanamide, (R)-N0-Benzyl 2-Amino-3,3-dimethylbutanamide, and (R)-N0-Benzyl 2-Amino-3-methoxypr… [cited by applicant]
Di Fiore B. et al., “The ABBA Motif Binds APC/C Activators and is Shared by APC/C Substrates and Regulators”, Journal, 2015, p. 358-372, vol. 32, Developmental Cell. [cited by applicant]
C.H. Golias, “Cell Proliferation and Cell Cycle Control: a Mini Review”, Journal, 2004, p. 1134-1141, vol. 58, Int. J. Clin. Pract. [cited by applicant]
Nugent R. et al., “I-H-11: Innovative therapy to halt proliferation of high mortality cancer tumour cells”, Report, 2021, p. 1-11, iCure Cohort H Patent Insights Report—Mathys & Squire Consulting. [cited by applicant]
Izawa D., “The mitotic checkpoint complex binds a second CDC20 to inhibit active APC/C”, Journal, 2014, p. 631-634, vol. 517, Nature. [cited by applicant]
Meadows, JC et al., “Sharpening the anaphase switch”, Journal, 2015, p. 19-22, vol. 43, Biochemical Society Transactions. [cited by applicant]
Yau, Mei-Kwan et al., “Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity”, Journal, 2015, p. 986-991, vol. 26, No. 3, Bioorganic & Medicinal Chemistry Letters. [cited by applicant]
Najda-Mocarska, Ewelina et al., “New thiourea organocatalysts and their application for the synthesis of 5-(1H-indol-3-yl)methyl-2,2-dimethyl-1,3-dioxane-4,6-diones a source of chiral 3-indoylmethyl ketenes”, Journal, 2… [cited by applicant]
Wang, Tzu-Hao et al., “Paclitaxel-Induced Cell Death”, Journal, 2000, p. 2619-2628, vol. 88, No. 11, Cancer 1. [cited by applicant]
Wang, Lixia et al., “Targeting Cdc20 as a novel cancer therapeutic strategy”, Author Manuscript, 2015, p. 141-151, vol. 151, Pharmacol Ther. [cited by applicant]
Zich, Judith et al., “Getting down to the phosphorylated ‘nuts and bolts’ of spindle checkpoint signalling”, Journal, 2010, p. 18-27, vol. 35, No. 1, Trends in Biochemical Sciences. [cited by applicant]